APA (7th ed.) Citation

M, P., J, Y., M, J., A, G., C, A., MA, A., . . . V, C. (2026). Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-26-0805

Chicago Style (17th ed.) Citation

M, Pelletier, et al. "Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody, NIS793, Plus Abraxane+gemcitabine Vs. Abraxane+gemcitabine Alone in a Phase II, Open Label, Randomized Study." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2026. https://doi.org/10.1158/1078-0432.CCR-26-0805.

MLA (9th ed.) Citation

M, Pelletier, et al. "Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody, NIS793, Plus Abraxane+gemcitabine Vs. Abraxane+gemcitabine Alone in a Phase II, Open Label, Randomized Study." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 2026, https://doi.org/10.1158/1078-0432.CCR-26-0805.